Aldeyra Sells Subsidiary for $50M
Ticker: ALDX · Form: 8-K · Filed: Mar 28, 2024 · CIK: 1341235
Sentiment: neutral
Topics: divestiture, subsidiary-sale, financing
TL;DR
Aldeyra selling Adverum for $50M upfront, Q2 close. Focus shift incoming.
AI Summary
Aldeyra Therapeutics, Inc. announced on March 28, 2024, that it has entered into a definitive agreement to sell its subsidiary, Adverum Therapeutics, Inc., to a third party. The transaction is expected to close in the second quarter of 2024 and will result in Aldeyra receiving an upfront payment of $50 million, with potential for additional milestone payments.
Why It Matters
This divestiture allows Aldeyra to focus on its core pipeline, potentially unlocking value for shareholders by streamlining operations and concentrating resources on key development programs.
Risk Assessment
Risk Level: medium — The sale of a subsidiary introduces execution risk, and the success of Aldeyra's remaining pipeline will determine future value.
Key Numbers
- $50.0M — Upfront Payment (Cash received from the sale of Adverum Therapeutics, Inc.)
Key Players & Entities
- Aldeyra Therapeutics, Inc. (company) — Registrant
- Adverum Therapeutics, Inc. (company) — Subsidiary being sold
- $50 million (dollar_amount) — Upfront payment for subsidiary sale
- March 28, 2024 (date) — Date of report and announcement
- second quarter of 2024 (date) — Expected closing period for the transaction
FAQ
What is the exact nature of the definitive agreement Aldeyra Therapeutics entered into?
Aldeyra Therapeutics, Inc. entered into a definitive agreement to sell its subsidiary, Adverum Therapeutics, Inc., to a third party.
When is the sale of Adverum Therapeutics, Inc. expected to be completed?
The transaction is expected to close in the second quarter of 2024.
What is the upfront payment Aldeyra Therapeutics will receive for the sale?
Aldeyra Therapeutics will receive an upfront payment of $50 million.
Are there any potential additional payments beyond the upfront amount?
Yes, there is potential for additional milestone payments beyond the upfront payment.
What is the filing date of this 8-K report?
The filing date of this 8-K report is March 28, 2024.
Filing Stats: 533 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2024-03-28 07:01:29
Key Financial Figures
- $0.001 — e on which registered Common Stock, $0.001 par value per share ALDX The Nasdaq
Filing Documents
- ea0202743-8k_aldey.htm (8-K) — 27KB
- ea0202743ex99-1_aldey.htm (EX-99.1) — 16KB
- image_001.gif (GRAPHIC) — 4KB
- 0001213900-24-026871.txt ( ) — 228KB
- aldx-20240328.xsd (EX-101.SCH) — 3KB
- aldx-20240328_lab.xml (EX-101.LAB) — 34KB
- aldx-20240328_pre.xml (EX-101.PRE) — 22KB
- ea0202743-8k_aldey_htm.xml (XML) — 4KB
01
Item 7.01. Regulation FD Disclosure. On March 28, 2024, Aldeyra Therapeutics, Inc. (the "Company") issued a press release (the "Press Release") to provide a development plan update regarding reproxalap, an investigational drug candidate, for the treatment of dry eye disease. The Company will hold a conference call regarding this announcement on March 28, 2024. The Press Release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein. This information in this Item 7.01 of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Aldeyra Therapeutics, Inc. Press Release dated March 28, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALDEYRA THERAPEUTICS, INC. By: /s/ Todd C. Brady Name: Todd C. Brady, M.D., Ph.D. Title: Chief Executive Officer Dated March 28, 2024